D-Galactose


CAS No. : 59-23-4

(Synonyms: D-(+)-Galactose)

59-23-4
Price and Availability of CAS No. : 59-23-4
Size Price Stock
100g $17 In-stock
500g $54 In-stock
1000g $79 In-stock
> 2 kg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-N0210
M.Wt: 180.16
Formula: C6H12O6
Purity: >98 %
Solubility: DMSO : 50 mg/mL (ultrasonic);H2O : 62.5 mg/mL (ultrasonic;warming;heat to 60°C)
Introduction of 59-23-4 :

D-Galactose is a natural aldohexose and C-4 epimer of glucose. In Vitro:Galactose is important for the survival and virulence of bacteria. In Escherichia coli galactose is utilized by the Leloir pathway. Two anomers of d-galactose are used for different purposes, α-d-galactose as a carbon source and β-d-galactose for induction of UDP-galactose synthesis for biosynthetic glycosylation[1]. In Vivo:Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

D-Galactose can be used in animal models to create subacute aging models in mice and cataract models in rats. Chronic D-galactose exposure induces neurodegeneration by enhancing caspase-mediated apoptosis and inhibiting neurogenesis and neuronal migration in mice, as well as increasing oxidative damage. Moreover, D-galactose-induced toxicity in mice serves as a useful model for studying the mechanisms of neurodegeneration and the evaluation of neuroprotective drugs and agents. Oral administration of D-galactose leads to cognitive impairment in rats, accompanied by oxidative damage. Cognitive impairments are observed in the open field test at the 4th and 6th weeks post-administration, and spatial memory deficits are noted in the radial arm maze test after the 6th week. D-Galactose is a classic agent for inducing subacute aging and cataract models. D-galactose alters protein and peptide structures by reacting with their free amino groups, leading to the accumulation of advanced glycation end-products (AGEs) during nonenzymatic glycation.

Induction of subacute aging model[5]
Background
D-galactose changes the structure of protein and peptide by reacting with their free amine groups resulting in the accumulation of advanced glycation end (AGE) products through non-enzymatic glycation. AGEs give rise to age-related disorders. Rats and mice are generally used as animal models.
Specific Modeling Methods
Mice: C57BL/6J • female • 8-week-old
Administration: 5, 100, 200 mg/day •s.c. • 8 weeks
Modeling Indicators
Body quality changes: Impaired spatial learning and memory of mice at a dose of 100 mg/kg.
Induced locomotor impairment in LAT in a dose-dependent manner especially in the second day.

Your information is safe with us.

Our product is for R&D purpose only.